Therapeutic | Eculizumab |
Target | C5 |
Heavy Chain | QVQLVQSGAEVKKPGASVKVSCKASGYIFSNYWIQWVRQAPGQGLEWMGEILPGSGSTEYTENFKDRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARYFFGSSPNWYFDVWGQGTLVTVSS |
Light Chain | DIQMTQSPSSLSASVGDRVTITCGASENIYGALNWYQQKPGKAPKLLIYGATNLADGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQNVLNTPLTFGQGTKVEIK |
100% seqID Fv Structure | 5i5k%3AHL%3AXY [Fvs: ] |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
100% seqID Structure | 5i5k%3AHL%3AXY [Fvs: ] |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G2 |
Highest Clinical Trial (August '23) | Approved |
Estimated Status (August '23) | Active |
Recorded Developmental Technology | GS Gene Expression System |
INN Year Proposed | 2002 |
INN Year Recommended | 2003 |
Companies Involved | Alexion Pharmaceuticals%3BBrigham and Womens Hospital%3BChiba University%3BHandok Inc |
Conditions Approved | Neuromyelitis optica%3BHaemolytic uraemic syndrome%3BMyasthenia gravis%3BParoxysmal nocturnal haemoglobinuria |
Conditions Active | Delayed graft function%3BGuillain-Barre syndrome%3BRenal transplant rejection%3BCOVID-19 |
Conditions Discontinued | Antiphospholipid syndrome%3BHeart transplant rejection%3BAdult respiratory distress syndrome%3BAge-related macular degeneration%3BAllergic asthma%3BAutoimmune haemolytic anaemia%3BBullous pemphigoid%3BDermatomyositis%3BGlomerulonephritis%3BIdiopathic thrombocytopenic purpura%3BLupus nephritis%3BMembranous glomerulonephritis%3BMotor neuron disease%3BPsoriasis%3BRheumatoid arthritis%3BSystemic lupus erythematosus |
Notes |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]